Table 2. RCTs investigating ovarian suppression with triptorelin during chemotherapy in patients with breast cancer.

Authors/year	POI	Time when POI evaluated months	No. of patients	Results	Conclusion
Lambertini et al. 2022 [54]	Amenorrhea and postmenopausal levels of FSH and E2	12	148 CT + GnRHa	POI rate	Prevention of POI
				8.9% vs. 25.9%
			133 CT	(p < 0.001)	No impact on DFS and OS
Elgindy et al. 2013 [55]	Amenorrhea	12	50 CT + GnRHa	POI rate	No prevention of POI
				20% vs. 20%
			50 CT	(p = 1.00)
Munster et al. 2012 [56]	Amenorrhea	24	27 CT + GnRHa	POI rate	No prevention of POI
				15% vs. 14%
			22 CT	(p = 0.32)
				Pregnancies: 0 vs. 2
Jiang et al. 2013 [57]	Amenorrhea	--	10 CT + GnRHa	POI rate:	Prevention of POI
				10.0% vs. 45.5%
			11 CT	(p = 0.05)
Karimi-Zarchi et al. 2014 [58]	Amenorrhea	6	21 CT + GnRHa	POI rate	Prevention of POI
				9.5% vs. 66.7%
			21 CT	(p < 0.001)

Note: CT: chemotherapy, POI: premature ovarian insufficiency, FSH: follicle-stimulating hormone, E2: estradiol, DFS: disease-free survival. OS: overall survival.